Doctors in Australia lead Phase 3 theranostics study targeting advanced prostate cancer

November 6, 2024 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Doctors in Perth are the first researchers to activate, enrol and deliver patient treatment in a multinational, multicentre Phase 3 nuclear medicine trial known as ProstACT GLOBAL, a study targeting advanced prostate cancer. …

Subscribe now to continue reading.

Latest Video

New report highlights widening gap in access to modern medicines between Australia and NZ
October 8, 2025 - Latest News
AstraZeneca becomes the latest to say it could halt UK investment over 'appalling' pricing regime
October 7, 2025 - Latest News
Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs
October 9, 2025 - Latest News
CUREator opens $33 million funding round with CSL and AbbVie partnership
October 8, 2025 - Latest News
AusBiotech’s annual report highlights a defining year for Australia’s life sciences sector
October 7, 2025 - Australian Biotech

Doctors in Australia lead Phase 3 theranostics study targeting advanced prostate cancer

This is a preview of subscriber content

Latest Video

Most Read

New report highlights widening gap in access to modern medicines between Australia and NZ

AstraZeneca becomes the latest to say it could halt UK investment over 'appalling' pricing regime

Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs

CUREator opens $33 million funding round with CSL and AbbVie partnership

AusBiotech’s annual report highlights a defining year for Australia’s life sciences sector

New Stories

This exchange on the HTA Review was about as underwhelming as it sounds

AusBiotech unveils international conference program for Australia’s biggest week in biotech

Life sciences industry calls for stronger national strategy to support trials and innovation

Officials outline ongoing measures to address ADHD medicine shortages

Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs

Australian company reports positive outcome from collaboration

CUREator opens $33 million funding round with CSL and AbbVie partnership

Sign In

Doctors in Australia lead Phase 3 theranostics study targeting advanced prostate cancer

This is a preview of subscriber content

Latest Video

Most Read

New report highlights widening gap in access to modern medicines between Australia and NZ

AstraZeneca becomes the latest to say it could halt UK investment over 'appalling' pricing regime

Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs

CUREator opens $33 million funding round with CSL and AbbVie partnership

AusBiotech’s annual report highlights a defining year for Australia’s life sciences sector

Follow Us

New Stories

This exchange on the HTA Review was about as underwhelming as it sounds

AusBiotech unveils international conference program for Australia’s biggest week in biotech

Life sciences industry calls for stronger national strategy to support trials and innovation

Officials outline ongoing measures to address ADHD medicine shortages

Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs

Australian company reports positive outcome from collaboration

CUREator opens $33 million funding round with CSL and AbbVie partnership